Harris James Associates News: Nautic Partners buys Omnicare Clinical Research
By PBN Staff, PROVIDENCE – Private equity firm Nautic Partners acquired Omnicare Clinical Research on
Thursday.
Harris James Associates News Compilation - JHA mission is to embrace our client s goals as our own and to work
as an extension of the client...
More
Harris James Associates News: Nautic Partners buys Omnicare Clinical Research By PBN Staff, PROVIDENCE – Private equity firm Nautic Partners acquired Omnicare Clinical Research on Thursday. Harris James Associates News Compilation - JHA mission is to embrace our client s goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful. Omnicare CR, headquartered in King of Prussia, Pa. , conducts early phase, phase II, III and late phase clinical trials for pharmaceutical, biotechnology and medical device industries. It also provides technical services supporting clinical trials, with a focus on data management and biostatistics services. As part of the deal, its parent company, Ominicare Inc. , has provided Omnicare CR with access to its proprietary database of de-identified information exclusive to the field of clinical research and lasting for five years. “Omnic
Less
From Harris James
Harris James Associates Biomedicine News: Can Hobbyists and Hackers Transform Biotechnology?
James Harris Associates mission is to embrace our client s goals as our own and to work as an extension of
the client organization to reach our common objective.
We know that we will be successful only if we make
our clients more successful....
More
Harris James Associates Biomedicine News: Can Hobbyists and Hackers Transform Biotechnology? James Harris Associates mission is to embrace our client s goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful. DIY Scientists Hack the Software of Life, Marcus Wohlsen explores the new movement in garage-based biotech. By Amanda Gefter. For most of us, managing our health means visiting a doctor. The more serious our concerns, the more specialized a medical expert we seek. Our bodies often feel like foreign and frightening lands, and we are happy to let someone with an MD serve as our tour guide. For most of us, our own DNA never makes it onto our personal reading list. Biohackers are on a mission to change all that. These do-it-yourself biology hobbyists want to bring biotechnology out of institutional labs and into our homes. Following in the footsteps o
Less
From Harris James
Harris James Associates Update: Congressional forum on biotech jobs focuses on FDA By Keith Darcé
Harris James Associates Update: Overly cautious government regulators, threats to basic science research
funding and burdensome taxes are holding back job creation by drug and medical device companies and
slowing the delivery of...
More
Harris James Associates Update: Congressional forum on biotech jobs focuses on FDA By Keith Darcé Harris James Associates Update: Overly cautious government regulators, threats to basic science research funding and burdensome taxes are holding back job creation by drug and medical device companies and slowing the delivery of innovative new therapies to patients, biotechnology industry experts told federal lawmakers Thursday during a hearing in San Diego. James Harris Associates mission is to embrace our client s goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful. Most of the criticism was directed at the Food and Drug Administration, which approved 21 new drugs last year, compared to 36 in 2004. "There are whole areas (of drug development) that venture capitalists won t pursue because the regulatory barriers are too high," said David Gollaher, president
Less
From Harris James
Harris James Associates Compiled News: Young Biotech Firms Seek Long Term Relevance
James Harris Associates mission is to embrace our client s goals as our own and to work as an extension of the client
organization to reach our common objective.
We know that we will be successful only if we make our clients more
successful.
The...
More
Harris James Associates Compiled News: Young Biotech Firms Seek Long Term Relevance James Harris Associates mission is to embrace our client s goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful. The Bedford Report Provides Analyst Research on Vivus and Avanir Pharmaceuticals NEW YORK, NY--(Marketwire - April 18, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Vivus, Inc. (NASDAQ: VVUS) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Access to the full company reports can be
Less
From Harris James
Harris James Associates Compiled News: Anthera Pharmaceuticals Successfully Completes Interim
Biomarker Analysis
Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third
Safety Review of Varespladib Methyl
James Harris Associates mission is to embrace our client s goals as our own and to...
More
Harris James Associates Compiled News: Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl James Harris Associates mission is to embrace our client s goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful. VISTA-16 Study to Continue Global Enrollment HAYWARD, Calif. , April 18, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that enrollment in the Phase 3 VISTA-16 study of varespladib in Acute Coronary Syndromes (ACS) will continue based on the positive outcome of an interim biomarker analysis and review of available patient safety data. An independent statistician c
Less
From Harris James
United States
Facebook
Digg
del.icio.us
Furl
rededit
StumbleUpon